ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2021年09月30日 17時00分
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes
- System supports Pfizer-BioNTech COVID-19 Vaccine, could support Moderna Vaccine as well
シンガポール, 2021年09月30日 - (JCN Newswire) - The Agency for Science, Technology and Research (A*STAR) has developed an Automated Vaccine Inoculation Dispenser (AVID) system, which replaces the manual step of filling injection syringes with vaccine liquid. AVID is customised for vaccination centres set up by the Ministry of Health and operated by private healthcare providers.
AVID was designed to address the labour-intensive steps of the vaccination process to reduce the workload of healthcare providers, increase accuracy and productivity, and enhance personal safety as well. AVID currently supports the management of vials containing the Pfizer-BioNTech COVID-19 Vaccine, with potential to be customised for the Moderna Vaccine as well.
AVID was developed by researchers from A*STAR's Advanced Remanufacturing and Technology Centre (ARTC) and Singapore Institute of Manufacturing Technology (SIMTech), in collaboration with local systems integrator Sysmatic Global. The innovative HealthTech solution is the first of its kind to automate the extraction of vaccines from vials using a combination of robotic parts, smart sensors and digital technologies.
How it works:
- After thawing of the Pfizer-BioNTech COVID-19 Vaccine, it is diluted in the vial.
- Typically, healthcare providers would then have to extract individual doses of the vaccine (0.3 mL for the Pfizer-BioNTech COVID-19 Vaccine) using syringes. One vial of Pfizer-BioNTech COVID-19 vaccine contains six doses of vaccine after dilution(*).
- AVID automates this step of extraction of the vaccine from the vial into six individual syringes, including the dispersing of bubbles inside the syringes.
- AVID also automatically uncaps and recaps the syringes during the transfer of vaccine from vials to syringes.
- It is easy to use at just the push of some buttons, only needing simple training without any special qualifications required.
Benefits:
- Reduces workload of healthcare providers, by freeing them from the manual step of extracting vaccines from vials to syringes.
- Allows more focused attention by healthcare providers on interacting and communicating with people receiving the vaccinations.
- Increases productivity at vaccination centres via introduction of automated processes that are accurate, consistent, and fast.
- Reduces risks of cross-contamination and vaccine wastage via safe handling by the machine.
- Improves safety for healthcare providers by reducing the handling of sharp syringes during the extraction step.
- The machine's small footprint and low weight (less than 25kg) means it can be easily deployed to any vaccination centre.
Development and Deployment:
- AVID was developed within six weeks from conceptualisation. It is the result of a collaboration between A*STAR's ARTC and SIMTech, which provided expertise in robotics, automation and Industry 4.0 technologies, and Sysmatic Global, which designed, integrated and constructed the machine.
- AVID has been deployed in at least seven vaccination centres so far which administer the Pfizer-BioNTech COVID-19 Vaccine. Thomson Medical, a vaccination centre operator, also supported A*STAR in the development and trial of the machine.
(*) Health Sciences Authority, Singapore: fact sheet for healthcare providers administering Pfizer-BioNTech COVID-19 vaccine:
https://bit.ly/3ikKZYt
** AVID fact sheet: www.acnnewswire.com/pdf/files/AVID_ASTAR_Sysmatic_FINAL.pdf
For media queries and clarifications, please contact:
Mr Robin Chan
Head, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6826 6281
Mobile: +65 9830 2610
Email:
robin_chan@hq.a-star.edu.sg
Mr Khoo Kiak Nee
Director, Sysmatic Global
Tel : +65 6246 6859
Mobile : +65 9688 2502
Email :
knkhoo@sysmaticgpl.com
About A*STAR
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.
Follow us on
- Facebook:
https://www.facebook.com/ASTARSG/
- LinkedIn:
https://www.linkedin.com/company/astarsg/
- Instagram:
https://www.instagram.com/astarsg/
- YouTube:
https://www.youtube.com/astartv
- Twitter:
https://twitter.com/astarsg
About Sysmatic Global
Sysmatic Global Pte Ltd was established in 2010 as an appointed agent & solution provider for Nitto Seiko, Japan, assembly products. Through the years, we had developed our own design team and evolved to a system integrator providing innovative automation solutions improving customer factory productivity and quality. Coupled with In-house Precision Machining & Sheetmetal fabrication facilities, we strive to provide a full turnkey solution to our customers. Please visit www.sysmaticgpl.com.
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
The 26th Hong Kong Forum marks successful completion
Dec 03, 2025 22:44 JST
Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Dec 03, 2025 11:30 JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Dec 03, 2025 00:01 JST
NEC Launches AI Agent Service in Japan to Automate Procurement Negotiations Using AI
Dec 02, 2025 23:43 JST
Fujitsu develops new technology to support human-robot collaboration
Dec 02, 2025 23:26 JST
Fujitsu establishes international consortium to tackle disinformation/misinformation and new AI risks
Dec 02, 2025 22:55 JST
Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms
Dec 01, 2025 23:04 JST
Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials
Dec 01, 2025 22:43 JST
Fujitsu launches 'Fujitsu Accelerator Program for SPORTS' to create new value through Sports x Technology
Dec 01, 2025 22:14 JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 28, 2025 23:00 JST
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Nov 28, 2025 19:41 JST
MHI Publishes "MHI REPORT 2025" and "SUSTAINABILITY DATABOOK 2025"
Nov 28, 2025 19:05 JST
Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST
Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST
Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST
NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST
World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST
Fujitsu accelerates blue carbon certification with ocean digital twin technology
Nov 26, 2025 19:05 JST
More Latest Release >>